Orchid vs Pfizer

Side-by-side comparison of AI visibility scores, market position, and capabilities

Pfizer leads in AI visibility (93 vs 38)
Orchid logo

Orchid

EmergingHealthcare

General

Wilmington DE YC W23 AI clinical notes EHR for mental health therapists; $728K total ($500K YC seed Oct 2023) with HIPAA-compliant AI notes and EHR integration competing with SimplePractice for independent therapist documentation.

AI VisibilityBeta
Overall Score
D38
Category Rank
#472 of 596
AI Consensus
76%
Trend
stable
Per Platform
ChatGPT
41
Perplexity
37
Gemini
33

About

Orchid is a Wilmington, Delaware-based AI-powered EHR platform for mental health professionals — backed by Y Combinator (W23) with $728,000 in total funding including a $500,000 seed in October 2023 from Y Combinator — providing independent mental health clinicians (therapists, psychologists, counselors) with HIPAA-compliant AI clinical notes that integrate with any existing EHR, automating note-taking to free time for patient care. Launched Orchid AI in July 2024, with e-prescribing planned for 2025, Orchid streamlines the administrative workflows and clinical documentation burden that forces mental health professionals to spend 2-3 hours daily on paperwork that competes with patient care time. Founded in 2020, targeting the solo and small group independent mental health practice market.

Full profile
Pfizer logo

Pfizer

LeaderHealthcare Tech

Enterprise

Global biopharma with $63.6B FY2024 revenue; $43B Seagen ADC acquisition rebuilds post-COVID pipeline; patent cliff 2026-2028 for Eliquis; activist Starboard Value pushing restructuring.

AI VisibilityBeta
Overall Score
A93
Category Rank
#1 of 596
AI Consensus
80%
Trend
up
Per Platform
ChatGPT
94
Perplexity
89
Gemini
94

About

Pfizer is one of the world's largest biopharmaceutical companies, founded in 1849 by cousins Charles Pfizer and Charles Erhart in Brooklyn, New York, and now headquartered in New York City. The company trades on NYSE (PFE) and reported $63.6 billion in total revenues for FY2024, normalizing from pandemic highs of $100 billion-plus in 2021-2022 driven by Comirnaty COVID-19 vaccine revenues with BioNTech and Paxlovid COVID antiviral sales. CEO Albert Bourla has led a strategic pivot to reset the company's long-term growth profile, anchored by the landmark $43 billion acquisition of Seagen in December 2023, adding a world-class antibody-drug conjugate (ADC) oncology pipeline including Padcev, Tukysa, Adcetris, and Tivdak.

Full profile

AI Visibility Head-to-Head

38
Overall Score
93
#472
Category Rank
#1
76
AI Consensus
80
stable
Trend
up
41
ChatGPT
94
37
Perplexity
89
33
Gemini
94
43
Claude
92
40
Grok
98

Key Details

Category
General
Enterprise
Tier
Emerging
Leader
Entity Type
brand
company

Track AI Visibility in Real Time

Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.